Table 4.
Results deterministic analysis
| Avelumab + BSC | BSC | Difference | |
|---|---|---|---|
| Discounted (costs 4.0%, effects 1.5%) | |||
| Total LYs | 3.52 | 2.72 | 0.80 |
| Total QALYs | 2.62 | 1.99 | 0.63 |
| Total costs, € | 110,734 | 62,548 | 48,186 |
| ICER, €/LYs | 60,113 | ||
| ICER, €/QALYs | 76,450 | ||
| Undiscounted (0% costs, 0% effects) | |||
| Total LYs | 3.75 | 2.88 | 0.88 |
| Total QALYs | 2.80 | 2.11 | 0.69 |
| Total costs, € | 118,628 | 67,822 | 50,806 |
| ICER, €/LYs | 57,934 | ||
| ICER, €/QALYs, | 73,788 | ||
BSC best supportive care, ICER incremental cost-effectiveness ratio, LY life year, QALY quality-adjusted life year